Atorvastatin is most effective cholesterol lowering agent. Most recently it was found that apart from their primary actions on HMG-CoA reductase enzyme this can also modulates the immune functions and inflammatory processes by their effects on expression of signaling proteins most importantly Rho, Rac and Ras. Therefore atorvastatin may have beneficiary effects of different inflammatorydiseases and autoimmune diseases. Out of theses chronic obstructive pulmonary disease (COPD) is most common public health problem and its accounts for about 3rd leading cause of death worldwide. The main burden of COPD associated morbidity were due to its systemic complications and frequent exacerbations. Current therapy cannot efficiently decreases its systemic complications. Thus in this research project we evaluating the beneficial effects of Atorvastatin in COPD patients and compare it with standard anti-inflammatory drug which was Budesonide. This shows that Atorvastatin can effectively improve the Spirometric finding, also having positive impact on health related quality of life as assessed by BODE index and SGRQ and effectively decreases the chances of exacerbations. Thus Atorvastatin can becomes the mainstay adjuvant therapy beside of their cardiovascular protective effects in COPD patients by modulating the inflammatory processes.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
